Joincare Pharmaceutical Group Industry Co., Ltd.

简體(tǐ)中(zhōng)文(wén) | English



Investor Relations

Listed on the Shanghai Stock Exchange in June 2001, with a maximum market value of 47.5 billion



Your location：

Homepage

Investor Relations

Announcement

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization of TG-1000 Capsule

Categories:

Announcement

Time:

2024-08-12 17:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Re-Election of the Board of Directors and the Supervisory Committee

Categories:

Announcement

Time:

2024-08-06 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Third Extraordinary General Meeting

Categories:

Announcement

Time:

2024-08-06 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-Announcement on the Implementation of 2023 Profit Distribution of JCARE

Categories:

Announcement

Time:

2024-07-11 17:30:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization of Semaglutide Injection

Categories:

Announcement

Time:

2024-06-12 19:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation

Categories:

Announcement

Time:

2024-06-12 19:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Annual General Meeting

Categories:

Announcement

Time:

2024-06-07 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate

Categories:

Announcement

Time:

2024-05-27 18:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Anuual General Meeting

Categories:

Announcement

Time:

2024-05-17 17:00:00
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining The U.S. FDA Approval for The Company's Drug Cetrorelix Acetate for Injection

Categories:

Announcement

Time:

2024-04-26 18:00:00

Page up

...

Page down

Quick Navigation

Product

Online Mall

0755-33268688

Service Hotline

Quick

Navigation

Service

Hotline

0755-33268688

Joincare Pharmaceutical Group Industry Co., Ltd.

Official WeChat Official Account

Corporate Governance

Subscribe

Investor Service

Financial reports

Corporate Calendar

GDR release information

Corporate Governance

Subscribe

Investor Service

Financial reports

Corporate Calendar

GDR release information

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization of TG-1000 Capsule

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Re-Election of the Board of Directors and the Supervisory Committee

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Third Extraordinary General Meeting

Ad hoc announcement pursuant to Art. 53 LR-Announcement on the Implementation of 2023 Profit Distribution of JCARE

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization of Semaglutide Injection

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Annual General Meeting

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Anuual General Meeting

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining The U.S. FDA Approval for The Company's Drug Cetrorelix Acetate for Injection